HepatectomyITPB QoRNCT06957041
Intertransverse Process Block for Quality of Recovery Post-Open Hepatectomy
A study testing Intertransverse process block in people with Hepatectomy and Intertransverse Process Block, run by Chinese University of Hong Kong.
Trial summary
The study aims to assess the analgesic efficacy of the ITPB at the retro-SCTL space in patients undergoing major open hepatectomy surgery. This is assessed by: Primary Objective: Primary outcome measure: ● Assessing the quality of recovery 15 (QoR15) score at 24 and 48 hours Secondary outcome measure: Number of… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hepatectomy, Intertransverse Process Block, Quality of Recovery (QoR-15)
- What is being tested?
- Intertransverse process block
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2025to 1 Oct 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients aged 18-75 years of ASA I - III physical status classification undergoing open hepatectomy for benign or malignant liver lesion.
Who cannot join
- Patient refusal
- Patients who are unable to comprehend the QoR15 form
- Local or systemic infection
- Coagulopathy leading to absolute contraindication to regional anesthesia
- Contraindication to local anaesthetics (LA) such as LA allergy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Intertransverse Process Block on the Quality of Recovery Post-Open Hepatectomy: A Pilot Non-Randomised Study of Intervention
The study aims to assess the analgesic efficacy of the ITPB at the retro-SCTL space in patients undergoing major open hepatectomy surgery. This is assessed by:
Primary Objective:
Read more
Primary outcome measure:
● Assessing the quality of recovery 15 (QoR15) score at 24 and 48 hours
Secondary outcome measure:
- Number of anaesthetic and hypoesthetic dermatomes on the ventral and dorsal aspect of the thorax on both the sides at 30 minutes of block completion and during the post anaesthetic room (PACU) discharge
- Assessing the 24-hour area under the curve of postoperative pain numerical rating score (NRS, 0-10) at rest and deep breathing or upon use of triflow.
- Assessing the amount of postoperative morphine (mg) equivalent consumption at 24 and 48 hours
- Time to discharge from High dependency unit (HDU) or Intensive care unit (ICU)
Hypothesis:
The investigators hypothesize that the application of ITPB targeting the retro-SCTL space in patients undergoing open hepatectomy will improve overall quality of recovery and pain score.
- Being tested
- Intertransverse process block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intertransverse process blockProcedure or surgery
The patient(s) will receive a pre-induction Intertransverse process block as pilot study
| Study group | Role | What they receive |
|---|---|---|
| Open Hepatectomy Patient receiving the intertransverse process block | Experimental | Not described Receives: Procedure: Intertransverse process block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Recovery (QOR-15)
The QoR-15 scale is a global measure of postoperative recovery, with a score ranging from 0 (extremely poor QoR) to 150 (excellent QoR). The QoR-15 has since become the most widely reported measure of patient-assessed QoR after surgery. QoR-15 has no units.
Measured: 24 and 48 hours
Secondary outcomes (4)
Dermatomal blockade on Thorax 30 minutes upon block completion
To assess the number of anaesthetic and hypoesthetic dermatomes on the ventral and dorsal aspect of the thorax on both the sides at 30 minutes of block completion and during the post anaesthetic room (PACU) discharge. This will be done by ice block test. The blockade is considered positive if patient has a reduction in cold sensation over the tested dermatome compared to non-blocked areas such as forehead.
Measured: Up to 30 minutes after block completion
24 hours area under curve of postoperative pain score
Assessing the 24-hour area under the curve of postoperative pain numerical rating score (NRS, 0-10) at rest and deep breathing or upon use of triflow.
Measured: Up to 24 hours
Morphine consumption at 24 and 48 hours postoperatively
Assessing the amount of postoperative morphine (mg) equivalent consumption at 24 and 48 hours
Measured: At 24 and 48 hours postoperatively
Time to discharge from HDU / ICU
Time to discharge from High dependency unit (HDU) or Intensive care unit (ICU) up to 5 days
Measured: Up to 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2025
- Study start1 May 2025 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HepatectomyStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wing Sum Li, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06957041
- Sponsor's protocol ID
- CRE Ref. No. 2024.562
- Acronym
- ITPB QoR
- Status last verified
- Apr 2025
- First submitted
- 18 Apr 2025
- Last updated
- 4 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided